Ascendiant Capital Markets Issues Pessimistic Forecast for Plus Therapeutics (NASDAQ:PSTV) Stock Price

Plus Therapeutics (NASDAQ:PSTV) had its price target decreased by Ascendiant Capital Markets from $21.00 to $19.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Several other equities research analysts have also commented on PSTV. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of Plus Therapeutics in a research note on Thursday. D Boral Capital raised Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, HC Wainwright cut their price target on Plus Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Plus Therapeutics Trading Down 0.3%

Shares of PSTV stock opened at $0.49 on Friday. Plus Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.31. The stock has a market capitalization of $67.12 million, a P/E ratio of -0.22 and a beta of 0.77. The firm’s 50 day moving average is $0.58 and its 200 day moving average is $0.48.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. As a group, equities analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PSTV. Virtu Financial LLC purchased a new stake in Plus Therapeutics in the 1st quarter worth $38,000. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics in the second quarter valued at about $41,000. Susquehanna International Group LLP bought a new position in shares of Plus Therapeutics in the third quarter worth about $46,000. Scientech Research LLC purchased a new stake in shares of Plus Therapeutics during the third quarter worth about $100,000. Finally, Altium Capital Management LLC bought a new stake in Plus Therapeutics during the 3rd quarter valued at approximately $628,000. Institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.